AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	€0.7330	-2.27%	1,44,000
09/26/09	€0.7500	+1.35%	2,45,638
08/26/08	€0.7400	-1.99%	2,70,840
07/26/07	€0.7550	-0.66%	1,71,340
06/26/06	€0.7600	-1.68%	2,16,989

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 09:25:00 10/07/2026 pm IST			5-day change	1st Jan Change
0.7330 ^EUR	-2.27%		-5.17%	-52.28%

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	5.87Cr 6.71Cr 5.41Cr 5Cr 9.48Cr 639.51Cr 9.64Cr 65Cr 25Cr 315.04Cr 25Cr 25Cr 1.08TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.87Cr 6.71Cr 5.41Cr 5Cr 9.48Cr 639.51Cr 9.64Cr 65Cr 25Cr 315.04Cr 25Cr 25Cr 1.08TCr	EV / Sales 2026 *	48.9x	EV / Sales 2027 *	45.1x
Free-Float	72.29%	Yield 2026 *	-	Yield 2027 *	-

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
10/06	AB Science presents new data on Masitinib
18/05	AB Science S.A. announced that it has received $2.989368 million in funding	CI
13/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
29/04	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
29/04	AB Science announces successful capital increase

10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

10/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
10/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG
08/07	Ab Science : Nomination de Stéphane LEDERMANN en qualité de Président Directeur Général
01/07	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026

1 day	-2.27%
1 week	-5.17%
Current month	-17.18%
1 month	-19.45%
3 months	-38.40%
6 months	-50.47%
Current year	-52.28%

1 week	0.72	0.78
1 month	0.72	0.94
Current year	0.72	1.61
1 year	0.72	1.73
3 years	0.72	4.46
5 years	0.72	16.68
10 years	0.72	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/05	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/21/09	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/21/02	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.27%	-5.17%	-47.34%	-81.03%	6.71Cr
MERCK & CO., INC.	-1.22%	-4.65%	+47.04%	+12.35%	31TCr
MERCK KGAA	+0.07%	-4.09%	+22.06%	-4.22%	6.94TCr
HALOZYME THERAPEUTICS, INC.	-3.08%	-4.09%	+32.22%	+104.18%	903.83Cr
KYOWA KIRIN CO., LTD.	-1.23%	-0.84%	+6.26%	+1.52%	855.94Cr
SK BIOPHARMACEUTICALS CO., LTD.	+2.74%	-4.41%	-16.77%	+12.26%	429.75Cr
BETTA PHARMACEUTICALS CO., LTD.	+1.60%	-9.66%	+14.44%	+27.14%	408.67Cr
YUHAN CORPORATION	+1.63%	-2.70%	-38.89%	+27.08%	340.27Cr
SUPERNUS PHARMACEUTICALS, INC.	-0.59%	+0.85%	+46.23%	+62.45%	281.26Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.24%	-2.33%	+11.41%	-21.98%	213.91Cr
Average	-0.01%	-2.53%	+7.66%	+13.98%	4.09TCr
Weighted average by Cap.	-0.93%	-3.41%	+39.70%	+11.76%

	2026 *	2027 *
Net sales	12L 13.72L 11.07L 10.22L 19.4L 13Cr 19.72L 1.32Cr 51.93L 6.45Cr 51.51L 50.39L 22Cr	13L 14.86L 11.99L 11.07L 21.01L 14Cr 21.37L 1.43Cr 56.26L 6.98Cr 55.8L 54.59L 24Cr
Net income	-	-
Net Debt	-	-